Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Product sales	$ 356,916	$ 311,881	$ 257,922
Contract manufacturing	42,968	30,944	0
Contracts, grants and collaborations	122,905	107,313	54,823
Total revenues	522,789	450,138	312,745
Operating expenses:
Cost of product sales and contract manufacturing	124,295	118,412	62,127
Research and development	153,997	150,829	119,933
Selling, general and administrative	148,458	122,841	87,883
Income from operations	96,039	58,056	42,802
Other income (expense):
Interest income	572	320	139
Interest expense	(6,523)	(8,240)	0
Other income (expense), net	(319)	2,926	426
Total other income (expense)	(6,270)	(4,994)	565
Income before provision for income taxes	89,769	53,062	43,367
Provision for income taxes	26,899	16,321	13,108
Net income	62,870	36,741	30,259
Net loss attributable to noncontrolling interest	0	0	876
Net income attributable to Emergent BioSolutions Inc.	$ 62,870	$ 36,741	$ 31,135
Earnings per share - basic (in dollars per share)	$ 1.63	$ 0.98	$ 0.86
Earnings per share - diluted (in dollars per share)	$ 1.41	$ 0.88	$ 0.85
Weighted-average number of shares - basic (in shares)	38,595,435	37,344,891	36,201,283
Weighted-average number of shares - diluted (in shares)	47,255,842	45,802,807	36,747,556